Not applicableApproved For MarketingNCT03906331
What this trial is testing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+4 more
Eli Lilly and Company